A pancreas can be surgically removed in a procedure called total pancreatectomy, and people do live for years afterward, though their daily life changes significantly. The operation eliminates all insulin production and all digestive enzyme secretion at once, so the person becomes permanently dependent on injected insulin and swallowed enzyme capsules with every meal. Total pancreatectomy is not a casual decision. It is typically reserved for situations where less radical surgery cannot solve the problem, such as centrally located pancreatic tumors or debilitating chronic pancreatitis that has not responded to other treatments.1PubMed Central. Total Pancreatectomy: Indications, Advantages and Disadvantages – A Review
Why Would Someone Need Their Entire Pancreas Removed?
The most common reason is cancer. When a tumor sits in the center of the pancreas or has spread through enough of the organ that a partial removal would leave cancerous tissue behind, surgeons may recommend taking the whole thing out. The goal is complete tumor clearance, which gives the best chance of preventing recurrence. For pancreatic adenocarcinoma specifically, even after total removal, five-year survival rates hover around 20% at experienced centers, while other tumors of the broader periampullary area have better long-term prospects.2Gastroenterology. Evolution and current status of the Whipple procedure: An update for gastroenterologists
Cancer is not the only indication, though. Severe chronic pancreatitis, particularly the small-duct variety that causes relentless pain, is another major reason. Some people have hereditary or genetic forms of pancreatitis that flare repeatedly over years despite medications, nerve blocks, and partial resections. For these patients, total pancreatectomy with autologous islet cell transplantation has become an increasingly accepted option. The indications have also expanded to include certain benign or borderline pancreatic tumors and cases where a remaining pancreatic stump from prior surgery is considered high-risk.3PubMed Central. Total Pancreatectomy with Autologous Islet Cell Transplantation-The Current Indications
Losing Insulin and the Other Hormones
The pancreas does two jobs. One is producing digestive enzymes (the exocrine function), and the other is producing hormones like insulin, glucagon, and amylin (the endocrine function). When the entire organ is gone, both functions disappear immediately. The result is a specific form of diabetes sometimes called type 3c diabetes or, more precisely, post-total-pancreatectomy diabetes.4PubMed Central. Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma
This version of diabetes is trickier to manage than the more familiar types 1 and 2. The problem is not just the absence of insulin. Glucagon, the hormone that raises blood sugar when it drops too low, is also gone. So is amylin, which normally helps slow digestion and prevent blood sugar spikes, and pancreatic polypeptide, which influences how the liver responds to insulin. Without glucagon as a safety net, injecting even slightly too much insulin can send blood sugar crashing into dangerous territory. This combination of absolute insulin deficiency with absent counter-regulatory hormones creates what clinicians describe as “brittle diabetes,” marked by wide glucose swings and a heightened risk of severe low blood sugar episodes.5PubMed. The unique pathophysiological features of diabetes mellitus secondary to total pancreatectomy: proposal for a new classification distinct from diabetes of the exocrine pancreas
Adding to the complexity, people without a pancreas tend to be more sensitive to insulin than a typical person with type 1 diabetes. That sounds like it would help, but it actually makes dosing harder. A small miscalculation has outsized effects. The direction of the error matters too: a partial pancreas removal on the tail side preferentially loses glucagon-producing cells, while removal of the head side preferentially loses pancreatic polypeptide cells, each creating different metabolic quirks.6PubMed. Pancreatic resection: effects on glucose metabolism
Digestion Without a Pancreas
Your pancreas normally releases a cocktail of enzymes, particularly lipase for fats, protease for proteins, and amylase for starches, into the small intestine after every meal. Without these enzymes, food passes through largely undigested, especially fat. The result is chronic diarrhea, oily stools, bloating, and weight loss. Left untreated, this leads to serious malnutrition and deficiencies in fat-soluble vitamins (A, D, E, and K).
The fix is pancreatic enzyme replacement therapy, or PERT: capsules of porcine-derived enzymes taken with every meal and snack for the rest of your life. Guidelines recommend starting at roughly 40,000 to 50,000 lipase units per meal and about half that with snacks, divided throughout eating rather than swallowed all at once before or after.7PubMed Central. Pancreatic Enzyme Replacement Therapy: A Concise Review Getting the dose right matters more than many patients realize. A systematic review of real-world data found that about 40% of studies reported average doses below the recommended range. At those lower doses, diarrhea often improved, but nutritional status did not. Patients who took guideline-level doses saw benefits in both symptom control and nutritional markers.8PubMed Central. Pancreatic Enzyme Replacement Therapy in Pancreatic Exocrine Insufficiency-Real-World’s Dosing and Effectiveness: A Systematic Review
Beyond enzymes, nutritional support after total pancreatectomy includes routine supplementation of calcium, vitamin D, selenium, and the other fat-soluble vitamins.9PubMed Central. Perioperative Nutritional Aspects in Total Pancreatectomy: A Comprehensive Review of the Literature In pediatric patients, a low-oxalate diet is also recommended to prevent kidney stones, since fat malabsorption changes how the body handles oxalate.10PubMed. Nutrition support in the pediatric total pancreatectomy with islet autotransplantation recipient
Delayed Gastric Emptying
One complication that catches many patients off guard is delayed gastric emptying, where the stomach takes much longer than normal to pass food into the intestine. It can cause nausea, vomiting, and an inability to eat normally for days or weeks after surgery. This affects roughly 10 to 15% of patients undergoing pancreatic resection.11Surgery. Optimal management of delayed gastric emptying after pancreatectomy: An analysis of 1,089 patients In one large series, nearly half of patients who developed delayed gastric emptying needed supplemental nutrition, either through a feeding tube or intravenous support, to bridge the gap until their stomach began working properly again.
The strongest predictor of delayed gastric emptying is the development of a postoperative pancreatic fistula, an abnormal connection where pancreatic secretions leak. Other contributing factors include the presence of abdominal fluid collections and more extensive surgery involving multiple organs.12PubMed. Delayed gastric emptying after distal pancreatectomy: A systematic review of the literature The condition is usually temporary, but it can extend a hospital stay by days or weeks and requires close monitoring.
Islet Autotransplantation
One of the most important developments in total pancreatectomy over the past few decades is the option of islet autotransplantation. During the surgery, after the pancreas is removed, a lab team quickly isolates the insulin-producing islet cells from the organ and infuses them into the patient’s liver through the portal vein. The hope is that some of those cells will engraft in the liver and continue producing insulin, sparing the patient from the most severe form of post-surgical diabetes.
The results are genuinely encouraging, though not a guaranteed cure. In one of the largest series reported, about 90% of patients achieved measurable islet function after transplant, as confirmed by detectable C-peptide (a marker of insulin production). At three years, roughly 30% were completely insulin independent, with the rate notably higher in children (about 55%) than adults (about 25%). Another third had partial function, meaning they still needed some insulin but had far more stable blood sugar than patients with no remaining islet function. Among patients with any graft function, about 82% maintained a hemoglobin A1c below 7%, a key threshold for good glucose control.13PubMed Central. Total pancreatectomy and islet autotransplantation for chronic pancreatitis
The number of islet cells that survive the isolation process is a critical predictor. Patients whose transplants yielded more than 5,000 islet equivalents per kilogram of body weight achieved insulin independence at three-year rates around 72%. Those with yields below 2,500 per kilogram had independence rates of only about 12%.13PubMed Central. Total pancreatectomy and islet autotransplantation for chronic pancreatitis Prior pancreatic surgery substantially reduces islet yield, which is one reason surgeons increasingly consider total pancreatectomy with islet autotransplantation earlier in the disease course rather than after multiple failed partial procedures.
Even for patients who do not achieve full insulin independence, partial graft function makes a meaningful difference. People with some residual islet activity experience fewer dangerous highs and lows, and they report better quality of life compared to those with no endogenous insulin production at all. In comparative studies, patients who received islet autotransplantation reported significantly less diabetes-related distress across nearly every measured category, from feelings of powerlessness to problems with hypoglycemia, compared to matched patients treated with insulin alone.14Communications Medicine. Quality of life and metabolic outcomes after total pancreatectomy and simultaneous islet autotransplantation
Technology Closing the Gap on Blood Sugar Control
For patients who do end up fully insulin dependent after surgery, technology is making the daily management more bearable. Automated insulin delivery systems, sometimes called artificial pancreas systems, pair a continuous glucose monitor with an insulin pump that adjusts doses in real time. A randomized trial tested a bihormonal artificial pancreas (delivering both insulin and glucagon) against standard care in total pancreatectomy patients. Patients using the device spent roughly 78% of their time in the normal glucose range, compared to about 57% with conventional management, and experienced dramatically less time in hypoglycemia.15JAMA Surgery. Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial
Fully closed-loop insulin delivery has also been tested during the chaotic postoperative period itself, when insulin needs fluctuate wildly. In a study comparing closed-loop systems to usual care for hospitalized patients recovering from pancreatic surgery, the automated system kept patients in target glucose range nearly twice as often without increasing the risk of low blood sugar.16PubMed Central. Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery In the pediatric population, commercially available automated systems have been used safely after total pancreatectomy with islet autotransplantation, with no episodes of diabetic ketoacidosis or severe assisted hypoglycemia reported.17Endocrine Practice. Automated Insulin Delivery System Use in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation
Quality of Life After Total Pancreatectomy
The honest picture is that life without a pancreas is harder than life with one, but it is livable and, for many patients, better than the disease state that led to surgery. A nationwide cohort study found that total pancreatectomy patients reported slightly lower global health scores (73 out of 100 versus 78 in the general population) and modestly lower daily health status. Interestingly, quality of life did not continue to deteriorate over time: patients surveyed at less than three years, three to five years, and more than five years after surgery reported similar scores. Most were satisfied with their diabetes management and experienced diabetes-related distress comparable to people with type 1 diabetes.18PubMed. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study
A systematic review covering multiple studies confirmed a moderately reduced overall quality of life score of about 76% compared to 86% in the general population. About 44% of patients reported ongoing symptoms related to exocrine insufficiency (diarrhea, fatty stools, bloating) during follow-up, which underscores why getting enzyme therapy right is not optional. On the diabetes side, readmission for endocrine-related problems occurred in about 19% of patients, though diabetes-related deaths were rare and essentially disappeared in studies limited to patients treated after 2005, reflecting improvements in both insulin therapy and monitoring technology.19PubMed Central. Systematic review of functional outcome and quality of life after total pancreatectomy
Fatty Liver Disease After Pancreatectomy
A less well-known complication is the development of fatty liver disease after pancreatic surgery. This is not the same as the fatty liver seen in people with obesity and metabolic syndrome. Instead, it appears to result from the metabolic disruption of losing pancreatic function, including poor fat absorption, malnutrition, and the metabolic shifts caused by the surgery itself. A systematic review found incidence rates as high as 75% in some series, with new fatty liver appearing within 12 months of surgery.20PubMed Central. De novo non-alcoholic fatty liver disease after pancreatectomy: A systematic review
That number probably overstates the problem for most patients. A multicenter prospective study in Japan found that about 20% of total pancreatectomy patients developed fatty liver within a year, and of those, roughly 38% saw it resolve by 12 months. Risk factors included female sex, higher body mass index before surgery, and postoperative diarrhea, the last of which is largely a marker of inadequate enzyme replacement.21PubMed. Incidence and risk factors of nonalcoholic fatty liver disease after total pancreatectomy: A first multicenter prospective study in Japan The practical takeaway is that aggressive nutritional support and adequate enzyme dosing are likely protective. Research has linked high-dose pancreatic enzyme therapy to reduced rates of post-surgery fatty liver.22PubMed. Clinical Characteristics and Risk Factors for the Development of Postoperative Hepatic Steatosis After Total Pancreatectomy
The Spleen Question
When only part of the pancreas needs to come out, particularly the tail, the spleen often gets removed along with it because the two organs share blood vessels. But this is not always necessary, and preserving the spleen has real benefits. Spleen preservation is associated with lower rates of postoperative infections, fewer blood clots, and better long-term immune function.23PubMed Central. Indications and techniques for minimally invasive spleen-preserving distal pancreatectomy In a total pancreatectomy, the spleen is almost always removed because of the extent of the dissection. This means patients lose the spleen’s role in fighting certain bacterial infections, particularly encapsulated organisms. Vaccination against pneumococcus, meningococcus, and Haemophilus influenzae is standard practice before or after surgery, and some patients take prophylactic antibiotics long-term.
Mental Health and the Burden of Chronic Pain
The population that undergoes total pancreatectomy with islet autotransplantation for chronic pancreatitis has a strikingly high burden of psychiatric illness, much of it predating the surgery. In one large series, 59% of patients had a preexisting psychiatric diagnosis documented before surgery, with depression (43%) and anxiety (33%) being most common. Opioid use at baseline was present in 57%, reflecting the severity of pain that leads people to consider this operation in the first place. During a median follow-up of nearly four years, 21% developed new psychiatric diagnoses, and 45% continued or started psychotropic medications.24PubMed Central. Psychiatric Comorbidities in Patients Undergoing Total Pancreatectomy With Islet Cell Autotransplantation and Associated Mortality
These numbers matter beyond the obvious human cost because preexisting psychiatric illness was associated with lower rates of insulin independence after islet transplantation and higher rates of chronic opioid use at follow-up. Whether the psychiatric conditions directly impair islet engraftment or whether they lead to behaviors (poor self-care, medication non-adherence, continued opioid exposure) that undermine outcomes is unclear. Either way, the data argue for integrating mental health support as a standard part of surgical planning and long-term care, not treating it as an afterthought.
Bioartificial Pancreas Research
For people living without a pancreas, the most tantalizing research involves bioartificial pancreas devices: engineered tissues or encapsulated cells that could produce insulin inside the body without requiring daily injections or an external pump. The concept involves placing insulin-producing cells, potentially derived from stem cells, inside biocompatible capsules that protect them from the immune system while allowing glucose and insulin to pass through. In preclinical studies, these encapsulated islets have shown promise, and if the technology translates to human use, it could serve as an alternative to both daily insulin therapy and whole organ transplantation.25PubMed Central. Translational Medicine: Bench to Bedside Capturing Islet Stem Cells for a Bio-Artificial Pancreas
The advantage of a tissue-engineered approach is that, at least in theory, the source of cells is unlimited. Traditional islet transplantation from donor pancreases is limited by organ supply, and even autotransplantation depends on how many healthy islets can be salvaged from a diseased organ. Stem cell-derived islets combined with immune-shielding encapsulation could bypass both constraints.26Frontiers in Biomaterials Science. Advancing diabetes treatment: from human beta cell technology to bioartificial pancreas development These technologies remain in development, with most still in preclinical or early clinical stages. But for someone newly diagnosed with a condition that may eventually require total pancreatectomy, the trajectory of the field offers genuine reasons for cautious optimism that managing life without a pancreas will get easier.